David Gray

David Gray

Home Area: Immunity, Microbes, and Molecular Pathogenesis
Mentor: Donald Kohn
Research project:

David is researching gene therapy for the treatment of primary immunodeficiencies. His project focuses on CRISPR/Cas9 mediated gene editing for therapeutic treatment of X-Linked Agammaglobulinemia.

Publications:

Hematopoietic Stem Cell Gene Therapy: Progress and Lessons Learned – Morgan RA, Gray D, Lomova A, and Kohn DB. Hematopoietic Stem Cell Gene Therapy: Progress and Lessons Learned. Cell Stem Cell. 2017; 21(5): 574-590. doi: 10.1016/j.stem.2017.10.010. PMID: 29100011.

Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells – Hoban MD, Cost GJ, Mendel MC, Romero Z, Kaufman ML, Joglekar AV, Ho M, Lumaquin D, Gray D, Lill GR, Cooper AR, Urbinati F, Senadheera S, Zhu A, Liu PQ, Paschon DE, Zhang L, Rebar EJ, Wilber A, Wang X, Gregory PD, Holmes MC, Reik A, Hollis RP, and Kohn DB. Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells. Blood. 2015; 125(17): 2597-2604. doi: 10.1182/blood-2014-12-615948. PMID: 25733580

Limiting Cholesterol Biosynthetic Flux Spontaneously Engages Type I IFN Signaling – York AG, Williams KJ, Argus JP, Zhou QD, Brar G, Vergnes L, Gray EE, Zhen A, Wu NC, Yamada DH, Cunningham CR, Tarling EJ, Wilks MQ, Casero D, Gray DH, Yu AK, Wang ES, Brooks DG, Sun R, Kitchen SG, Wu TT, Reue K, Stetson DB, and Bensinger SJ. Cell. 2015; 163(7): 1716-29. doi: 10.1016/j.cell.2015.11.045. PMID: 26686653